Latest / Stock Movers / NatWest Rises, Sanofi Climbs, Saab Surges
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Let's take a look at some of the stocks on
- 0:18Speaker 3: the mood today here in Europe. I'm Caroline Hepca with
- 0:20Speaker 3: Tom McKenzie with John Bupplinberg's Colomba Lay. Good morning, more
- 0:23Speaker 3: loads of earnings to think about in Europe. Let's start
- 0:26Speaker 3: with that West the lender raising its guidance.
- 0:28Speaker 1: Yeah, very good morning for Network with a positive update
- 0:30Speaker 1: kind of across the board. So, as you mentioned, raised
- 0:33Speaker 1: its income and returns guidance, also delivered its highest earnings
- 0:36Speaker 1: in at least a decade. And then also the net
- 0:39Speaker 1: interest margin, which is really a key measure of profitability,
- 0:42Speaker 1: was also higher. It also set aside lesson expected to
- 0:46Speaker 1: cover bad loans, which kind of suggests that the quality
- 0:49Speaker 1: of its loan portfolio is in good shape. This is
- 0:52Speaker 1: the third UK bank to report this week. We had
- 0:55Speaker 1: Barclay's and Lloyd's as well earlier, and arguably Networks is
- 0:58Speaker 1: the one that delivered the most impressive results and therefore
- 1:01Speaker 1: has seen the biggest kind of reward by the market,
- 1:03Speaker 1: with shares really rising this morning, but overall the UK
- 1:07Speaker 1: banking sector seems to be doing pretty well. Both Lloyds
- 1:11Speaker 1: and Barclays also upgraded at least part of their guidance.
- 1:14Speaker 1: Barclay's obviously a new buyback, and they've all kind of
- 1:17Speaker 1: signaled that UK customers are resilient and coping quite well
- 1:20Speaker 1: with inflation and with a weaker jobs market. We do
- 1:24Speaker 1: have the budget come in next month. Of course, all
- 1:26Speaker 1: of that might change, but for now UK banks are
- 1:29Speaker 1: holding up well, and that Works in particular is holding
- 1:31Speaker 1: up very well.
- 1:32Speaker 3: Okay, So from the banking space to the pharmaceutical space.
- 1:36Speaker 3: Sonafi are also in focus and profit rising more more
- 1:40Speaker 3: than expected last quarter.
- 1:41Speaker 1: Yeah, profit beat because of really strong demand for its
- 1:44Speaker 1: blogbuster asthma drug called jupix and so the sales of
- 1:48Speaker 1: Jupixen reached a record in the quarter and it's expected
- 1:52Speaker 1: to generate more than twenty one billion euros in annual
- 1:55Speaker 1: revenue at its peak, which makes it so Nophi's most
- 1:58Speaker 1: important biggest medice by quite a long shot. That profit
- 2:02Speaker 1: be and the fact that gupis and cells were really
- 2:05Speaker 1: solid overshadowed was well. Another part of the earnings, which
- 2:09Speaker 1: was a bit of more bit more of a weak spot,
- 2:11Speaker 1: which is the vaccine segment. So so Nofi said that
- 2:14Speaker 1: cells of flu shots fell quite significantly. It blamed that
- 2:17Speaker 1: on price competition in Europe and then also lower vaccination
- 2:21Speaker 1: rates in the US. The CFO also said there was
- 2:24Speaker 1: maybe a little bit of post covid fatigue and quite
- 2:26Speaker 1: negative as sentiment around vaccines, which obviously could be quite
- 2:30Speaker 1: a challenge going forward for so Nofie and other pharmaceutical peers.
- 2:35Speaker 1: On the tariff side of things, and IPHI said it
- 2:37Speaker 1: is in constant discussions with the US, though it actually
- 2:41Speaker 1: did not make a deal like we've seen with Faiso
- 2:44Speaker 1: or Aslanka or merk where we've seen those companies trying
- 2:47Speaker 1: to well cutting a deal with the US to lower
- 2:50Speaker 1: drug costs in exchange for that tariff relief. So so
- 2:52Speaker 1: Nofia has not done that yet, but it is in
- 2:55Speaker 1: discussion with the US about those tariffs.
- 2:58Speaker 3: Okay, So that's on the farmer's story. Very US dependent too,
- 3:03Speaker 3: isn't it. Let's also think about defense and the momentum
- 3:08Speaker 3: that SAAB has. The CEO also making some comments speaking
- 3:12Speaker 3: to Bloomberg.
- 3:12Speaker 1: Yeah, absolutely, so the Swedish defense company It boosted its
- 3:16Speaker 1: revenue guidance this morning. It said that it's obviously benefiting
- 3:19Speaker 1: from the uncertain geopolitical landscape that we are dealing with
- 3:23Speaker 1: at the moment and all the tensions across the world.
- 3:26Speaker 1: It said that it's got a record high order backlog,
- 3:28Speaker 1: a really strong demand and as you said, the CEO
- 3:31Speaker 1: was on Bloomberg TV and saying that he expects that
- 3:34Speaker 1: momentum to be sustained going forward. We also had another
- 3:37Speaker 1: positive update that this morning from another defense company, Hensalt
- 3:41Speaker 1: in Germany, which provided margin guidance. There was also a
- 3:45Speaker 1: head of estimates and the stock rose quite a bit
- 3:47Speaker 1: on the back of that as well. It seems that
- 3:50Speaker 1: the boost from increased military spending is really starting to
- 3:53Speaker 1: feed through for those defense companies, with orders starting to
- 3:57Speaker 1: translate into profit. And given that attempt to broke a
- 4:00Speaker 1: piece in Ukraine seem to be facing quite a lot
- 4:02Speaker 1: of obstacles that will be probably continuing as well.
- 4:07Speaker 2: The Stockmover's report from Bloomberg Radio. Check back with us
- 4:11Speaker 2: throughout the day for the latest roundup of companies making
- 4:14Speaker 2: news on Wall Street and for the latest market moving headlines.
- 4:18Speaker 2: Listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg
- 4:22Speaker 2: dot com, and on Applecarplay and Android Auto with the
- 4:25Speaker 2: Bloomberg Business app.